WO1998016634A1 - Expression transgene - Google Patents
Expression transgene Download PDFInfo
- Publication number
- WO1998016634A1 WO1998016634A1 PCT/GB1997/002830 GB9702830W WO9816634A1 WO 1998016634 A1 WO1998016634 A1 WO 1998016634A1 GB 9702830 W GB9702830 W GB 9702830W WO 9816634 A1 WO9816634 A1 WO 9816634A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- transgene
- genetic construct
- flanking
- expression
- transgenic
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 73
- 108700019146 Transgenes Proteins 0.000 title claims description 101
- 230000009261 transgenic effect Effects 0.000 claims abstract description 47
- 108020004414 DNA Proteins 0.000 claims abstract description 36
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 29
- 230000002068 genetic effect Effects 0.000 claims abstract description 26
- 108091026890 Coding region Proteins 0.000 claims abstract description 25
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 20
- 230000001105 regulatory effect Effects 0.000 claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 33
- 239000013598 vector Substances 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 26
- 241001465754 Metazoa Species 0.000 claims description 17
- 241001529936 Murinae Species 0.000 claims description 17
- 108020005065 3' Flanking Region Proteins 0.000 claims description 14
- 241000282414 Homo sapiens Species 0.000 claims description 12
- 108020005029 5' Flanking Region Proteins 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 9
- 241001494479 Pecora Species 0.000 claims description 7
- 238000003306 harvesting Methods 0.000 claims description 5
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 102000051631 human SERPINA1 Human genes 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 description 29
- 239000013612 plasmid Substances 0.000 description 14
- 238000011830 transgenic mouse model Methods 0.000 description 14
- 238000010276 construction Methods 0.000 description 12
- 102000008192 Lactoglobulins Human genes 0.000 description 11
- 108010060630 Lactoglobulins Proteins 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 230000010354 integration Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 210000005075 mammary gland Anatomy 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 241000699660 Mus musculus Species 0.000 description 8
- 239000013601 cosmid vector Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000002759 chromosomal effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000009795 derivation Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 230000010474 transient expression Effects 0.000 description 3
- 238000003146 transient transfection Methods 0.000 description 3
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108010025815 Kanamycin Kinase Proteins 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 101150055766 cat gene Proteins 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000003153 stable transfection Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000594011 Leuciscus leuciscus Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4717—Plasma globulins, lactoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/103—Ovine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Definitions
- the invention relates to a genetic construct which causes improved expression of a protein and/or RNA coding sequence when the construct is introduced into a host organism, vectors which include the construct, transgenic organisms which provide improved expressed of such a coding sequence and a method for the production of such a transgenic organism.
- Transgenic organisms are today common tools in areas of technology such as medicine, agriculture and food production.
- One specific use, of considerable potential is of transgenic organisms as bioreactors for protein production.
- Of particular benefit is the use of transgenic livestock as bioreactors for the production of human proteins .
- transgenic organisms as bioreactors requires the ability to repeatedly provide transgenic organisms with high levels of transgene expression. To date, this has not been achieved. Observations in transgenic organisms are that the same transgene construct varies widely in its level of expression in different transgenic lines.
- One theory for this course of variation is that the chromosomal sequence at the site of integration affects expression. This is referred to as the "position effect" and is discussed in WO 92/11358 and in Al-Shawi et al (Mol . Cell . Biol . 10, 1192-98 (1990)).
- WO 92/11358 teaches that position effects could be overcome by integrating a poorly expressed transgene in the region of an efficiently expressed transgene. This enabled the poorly expressed coding sequence to overcome the negative position effects, and consequently, to exhibit enhanced expression. However, in order to achieve enhanced expression of a poorly expressed transgene in that case, cointegration of coding sequences was required.
- transgenes are very highly expressed irrelevant of their site of integration in the host chromosome. Such transgenes are considered to "dominate” just any site into which they integrate and so overcome any effects mediated by the endogenous DNA. Unfortunately this ability to "dominate” and thus result in high expression is limited to a small number of transgenes .
- the ability to produce high levels of expression of a selected transgene in lines of transgenic animals would be of enormous importance. Of additional importance would be a method for the production of transgenic lines which have some degree of commensurate and predictably enhanced transgene expression level.
- the present invention contributes towards the achievement of such goals.
- the present invention is based on the premise that in most cases endogenous sequences at the site of integration of a transgene may be directly responsible for the result of the observed "position effects". This follows the proposition that the site of integration of transgenes is random and that sequences in the host genome possess an inherent ability for expression of such integrated DNA (i.e. some sites in the genome are more permissive for expression than others) .
- transgene would have integrated into a permissive site.
- transgenes can be used as probes for the identification of such permissive and non-permissive sites in a host which has been transformed with that transgene.
- a genetic construct comprising sufficient regulatory sequence operatively linked to a protein and/or RNA coding sequence to direct its expression and sufficient flanking DNA from a highly expressed transgenic loci to cause improved expression of the protein and/or RNA coding sequence when the construct is introduced into a host organism.
- transgene is intended to include any nucleic acid sequence, including cDNA, which encodes all or part of any polypeptide (coding sequence) that is operatively linked to sufficient regulatory DNA sequences to direct its expression.
- the nucleic acid may be derived from any source, including the genome of the host animal. Both of the terms “transgene” and “coding sequence” encompass nucleic acid sequences of foreign and endogenous derivation.
- flanking DNA is intended to include all or any part of a sequence corresponding to the flanking sequences of any highly expressed transgenic loci which result in improved/enhanced expression of the transgene.
- Corresponding sequences include identical sequences or variations thereof including, in particular, the replacement of a purine base by another purine base and the replacement of a pyrimidine base by another pyrimidine base which also result in improved/enhanced expression of the transgene.
- the flanking DNA may comprise either all or part of the 5' flanking sequence, all or a part of the 3' flanking sequence or all or a part of both the 5' and 3' flanking sequences from a highly expressed transgenic loci .
- Flanking sequences from transgenic loci can be isolated by conventional cloning techniques and vectors all of which are well known to those skilled in the art, including yeast artificial chromosomes (e.g. up to 1 megabase) , cosmid vectors or bacteriophages .
- the flanking DNA is all or part of both of the cloned 5' and 3' flanking sequences. Incorporation of such flanking DNA results in the improved expression of the transgene.
- the flanking sequence (s) are preferably located either side of the transgene, (ie the 5' flanking sequence is on the 5' side of the coding sequence and the 3' flanking sequence is on the 3' side of the coding sequence) .
- flanking sequences from a highly expressed transgenic loci are either or both of the flanking sequence from the secondary transgene TAB (including TAB 3' and TAB 5') contained in the cell line deposited under the Accession No. NCIMB 40806.
- Optimum expression levels of such a construct are obtained when both the 5 ' and 3 ' flanking sequences are present and preferably where the 5' flanking sequence is located on the 5' side of the transgene and the 3 ' flanking sequence is located on the 3' side of the transgene.
- the construct comprises the murine derived flanking DNA of the secondary transgene TAB contained in the cell line deposited under the Accession No.
- the coding sequence of the construct is preferably mammalian derived, most preferably human although it may have its derivation in one or more of any organism including humans, or non-human mammals, for example sheep, pigs and mice.
- suitable coding sequences according to the invention include human derived genes, for example the human gene(s) which encode alpha 1-antitrypsin, milk proteins and blood factors such as Factors VIII and IX.
- the host organism may be eukaryotic, including animal or plant.
- the choice of host preferably reflects the derivation of the regulatory sequence of the transgene, i.e. a transgene containing regulatory sequences derived from a mammal is preferably expressed in a mammalian host, suitably a non-human mammalian host.
- Suitable regulatory sequences operatively linked to the protein and/or RNA coding sequence (s) to direct its expression are well known in the art and can be selected according to requirement .
- An example of a suitable regulatory DNA sequences is the beta-lactoglobulin promoter. This particular promoter drives expression of the protein encoded by the coding sequence in the mammary gland of transgenic mammals, preferably non-human transgenic mammals.
- the selected coding sequence is targeted for expression to the mammary glands then it is essential that the host animal is a mammal.
- Suitable laboratory mammals for experimental ease of manipulation include mice and rats. Larger yields may be obtained from domestic animals such as cows, pigs, sheep and other mammals. Such domestic farm animals and 'intermediate' animals such as rabbits are most suitable as bioreactors for protein production.
- a vector which comprises a genetic construct according to any part of the first aspect of the invention.
- Suitable vectors are commonplace in the art and include the well known vectors Lambda DASH II
- an eukaryotic cell comprising a genetic construct according to any part of the first aspect of the invention.
- the genetic construct is part of a mammalian cell, suitably a non-human mammalian cell, more preferably a murine or ovine cell, most preferably a mammary gland cell or a liver cell.
- Methods for the introduction of genetic constructs into cells are well known in the art and include pronuclear injection and electroporation .
- a transgenic organism comprising a genetic construct according to the first aspect of the invention integrated into its genome, preferably a non-human transgenic organism.
- a transgenic organism can carry the integrated genetic material stably and which, as a result of the flanking sequence (s) associated with the transgene is capable of expressing at improved or enhanced levels, the integrated transgene.
- the transgenic organism is preferably a sheep or a mouse.
- a method of providing improved expression of a transgene from a transgenic host organism preferably a non-human transgenic organism.
- the method comprises introducing into the host organism a genetic construct according to any part of the first aspect of the invention.
- Techniques for introducing genetic constructs into organisms are well known in the art and include pronuclear injection and the use of ES cell or an equivalent route.
- the first method is exemplified in the examples of this application.
- the transgenic host is preferably a laboratory animal such as a mouse, rat or rabbit or a potential livestock bioreactor animal, including those described above as well as sheep or cattle.
- a method of obtaining a substance comprising a polypeptide comprising harvesting the substance from a transgenic organism according to the fourth aspect of the invention.
- the substance is either secreted from the organism for harvesting or is expressed at a specific location by the organism for harvesting.
- a preferred method for obtaining a substance according to this aspect of the invention is to direct expression of the coding sequence linked to a beta-lactoglobulin promoter and harvest the substance from the mammary gland of mammalian transgenic host organism.
- the mammal is a non-human mammal, for example a mouse or a sheep.
- FIGURE 1 shows various examples of a secondary transgene according to the invention including the relationship between the transgene and the flanking sequences .
- the open box at the top of the Figure (designated AATB) represents the primary transgene.
- FIGURE 2 shows a restriction map of the transgene locus of mouse line AATB 46.2.
- FIGURE 3 shows restriction maps of (a) clone 9 and (b) clone 8 which were isolated from the cosmid library from an animal of line AATB 46.2.
- FIGURE 4 shows a diagram of the Lambda DASH II vector (Stratagene) .
- FIGURE 5 shows the position of Notl and Srfl restriction sites: (a) in clone 8 and (b) in clone 9.
- FIGURE 6 shows a diagrammatic construction of the secondary transgene TAB from clones 8 and 9.
- FIGURE 7 is a graphic representation of AAT expression level from two studies of the transgenic mice containing the primary transgene AATB and one study of transgenic mice containing the secondary transgene TAB .
- FIGURES 8(a), 8(b) and 8(c) show the construction of a "high expressing" vector (named MV) which contains the 5' and the 3' flanking sequences from the plasmid TAB (pTAB) , deposited at NCIMB as deposit no. 40806.
- the MV vector can be used to prepare a plasmid for a high expressing transgene (either from that plasmid or from any other genetic construction following integration of plasmid sequences therewith) .
- FIGURE 9 shows the construct MV-BLG-CAT in which the BLG-CAT sequences were inserted between the 5' and 3 ' MV sequences.
- FIGURE 10 shows the results of experiments to determine the expression of MV-BLG-CAT constructs in HC-11 cells. The level of expression is measured by the %CAT conversion.
- FIGURE 11 shows the construct MV-SV40-CAT.
- FIGURE 12 shows the results of experiments to determine the expression of MV-SV40-CAT constructs in BHK cells .
- the level of expression is measured by the %CAT conversion.
- the transgenic mouse line designated AATB 46.2 harbours the transgene designated AATB.
- the transgene encodes human AAT.
- the expression of this protein in the mammary gland of the transgenic mice is driven by the ovine BLG promoter.
- This transgenic mouse line was constructed as described in WO 90/05188 on pages 12 to 23.
- the expression level of AAT from the line AATB 46.2 was observed as stable through several generations and ranged from 6-8 mg/ml.
- the locus of AATB 46.2 was mapped using a number of restriction endonucleases using techniques known in the art .
- the transgenes were found to be in a perfect head to tail array.
- a restriction map of the locus is given in Figure 2.
- the number of copies of the transgene in the line was approximately eight.
- the junction fragments detected using a number of restriction endonucleases and probes are represented with thick lines. The size of the junction fragment is given above each.
- transgenic mouse line AATB 46.2 was cloned by first constructing a cosmid library of DNA isolated from these mice in the cosmid vector Super COS
- the cosmid library was constructed using liver DNA from an animal of line AATB 46.2. The DNA was partially digested with the enzyme Ndell and fractionated on a sucrose gradient. Fractions containing fragments of
- the library was screened using the ovine 5' -BLG sequences.
- the enzyme Notl was used to liberate the AATB transgene from the pPoly-III-I vector sequences prior to micro-injection. This enzyme produces a 5' overhang of four base pairs at the transgene ends. Analysis of the clones demonstrated that the Notl site had been regenerated between the transgenes within the array. One of the clones included the murine sequences of the 5' end of the array and the other included the murine sequences from the 3 ' end of the array. Both clones were found to harbour a maximum of 5kb of murine sequences . The remainder of the insert sequences were those of the AATB transgene array.
- Both of the clones 8 and 9 generated Notl fragments of approximately 15 kb .
- the large Notl fragment from clone 9 encompassed the entire AATB transgene plus all of the murine flanking DNA within the insert. It spanned from the Notl site of the cosmid vector cloning region to the first Notl site within the transgene array. This was identified as the 5' junction fragment of the locus with respect to the 5' -3' orientation of the AATB transgenes within the array. Sequencing across the chromosomal /transgene junction demonstrated that the AATB transgene at the 5' end of the transgene array was intact. No digestion of the transgene end had occurred prior to integration into the genome.
- the large Notl fragment of clone 8 was similar. It encompassed the AATB transgene from the 3 ' end of the transgene array and the 3 ' flanking murine DNA of the AATB 46.2 locus. This fragment spanned from the most 3' Notl site in the array to the Notl site in the cosmid vector cloning region. Sequencing across the chromosomal /transgene junction in this clone demonstrated that 50bp of the AATB sequences had been removed from the end of the 3' transgene of the array before integration into the genome . This was the only perceptible damage that had occurred within the array.
- the secondary transgene was constructed from clone 8 and clone 9 and cloned in Stratagene 's Lambda DASH II phage vector.
- a diagram of this vector is given in Figure 4.
- the vector accommodates an insert of 14 to 20kb in size.
- Clones 8 and 9 are those described above in Example 3. Both clone 8 and clone 9 were digested with the restriction enzymes Srfl and Notl. The junction fragments produced by this digest were isolated from both clones.
- Figure 5 shows the position of Notl and Srfl restriction sites for clones 8 and 9. The fragments which were isolated and purified from the digests for the construction of the secondary transgene are underlined and the respective sizes of the fragments are given.
- the clone 9, Notl-Srfl junction fragment spanned from the Notl site of the cosmid vector to the Srfl site in the BLG sequence of the AATB transgene .
- the fragment was 8.7 kb in size and contained all of the murine genomic DNA from clone 9.
- the clone 8 Notl -Srfl junction fragment spanned from the Srfl site in the BLG sequences of the transgene to the Notl site of the cosmid vector.
- the fragment was llkb in size and contained the AAT coding sequences of the AATB transgene and all of the murine genomic DNA of clone 8.
- the secondary transgene has both the 5 ' murine flanking DNA from clone 9 and the 3 ' murine flanking DNA from clone 8. Between the 5' and 3' flanking genomic sequences is a single copy of the AATB transgene. This copy is missing 50bp from the 3' end of the AATB transgene . These sequences are within the non- transcribed 3' sequences of AATB.
- the secondary transgene also harbours the T3 and T7 primer sites from the cosmid vector. The secondary transgene has Notl ends and these were used to clone the transgene into the Lambda DASH II vector. A small number of recombinant phages were obtained from the ligation.
- plaques were screened using a 3' AATB probe and a 5' AATB probe. All but one of the plaques hybridised to both probes indicating that the AATB sequences from clone 9 and clone 8 must have been present within the inserts.
- the secondary transgene insert was purified from the lambda vector sequences following Notl digestion of the clone and was subsequently re-cloned into the pBluescript vector (Stratagene) to generated pTAB. This plasmid was deposited at NCIMB [NCIMB 40806] .
- the insert from pTAB was excised by Notl digestion and the injection fragment purified by gel electrophoresis.
- 12 secondary transgenic mouse lines were produced by pronuclear injection of newly fertilized mouse embryos. Construction of these secondary transgenic animals, including injection of DNA and identification of transgenic individuals was as described in WO 90/01588, pages 35 to 46. The transgenic animals were detected using both PCR and Southern blotting procedures. The expression levels of the human protein AAT in the milk of lactating secondary transgenic females was measured in the first produced transgenic animals (the G 0 generation) and in the subsequent generations (G 17 G 2 , etc.).
- Example 6 above is of a secondary TAB transgene, which includes the genomic flanking sequences from the 46.2 locus. The comparison of expression levels are given in
- FIG. 7 This compares the average level of expression of AAT in individually generated transgenic mouse lines for the Archibald Study, the Carver Study and the study with the secondary transgene (TAB) .
- TAB mice In the TAB mice, not only are more mice expressing higher levels of AAT but maximal levels of expression in the TAB group of mice is approximately 3 fold of that observed in either of the other mice studies .
- Construction of MV Vector Figures 8(a), 8(b) and 8(c) show the construction of a
- MV "high expressing" vector
- pTAB plasmid TAB
- the MV vector can be used to prepare a plasmid for a high expressing transgene (either from that plasmid or from any other genetic construction following integration of plasmid sequences therewith) .
- pBluescript is referred to as SK.
- (1) is the cloning of the Not-Sal 4kb fragment into pBlueSK at the appropriate Not and Sal sites.
- the Sal-Sal 0.6kb fragment is cloned into the SK4.0 Sal site and the orientation checked under item (2) .
- Figure 8 (b) shows the third step of partial digestion to delete the middle Sal site to generate SK 4.6D.
- the ligation of murine 5' and 3' flanking sequences is described as Notl and Sail digested flanking clone to release inserts, then ligating the result into pBlueSK Notl site to generate SK 9.6.
- the modification of the clone vector is described.
- the construct MV-BLG-CAT was generated using the MV vector (see Figure 8c) and a BLG-CAT hybrid gene using standard recombinant DNA techniques.
- the BLG-CAT gene comprises a 406kb beta-lactoglobulin (BLG) promoter element linked to the bacterial chloramphenicol acetylase gene (CAT) and has been previously described (Webster et al Cell Biol . Res . 41 11-15 (1995)).
- the CAT sequences provide a reporter gene whose expression can be conveniently be quantitated.
- the BLG-CAT sequences were inserted between the 5' and 3' MV sequences as illustrated in Figure 9.
- the Notl fragment released from the BLG-CAT plasmid was cloned into the Smal restriction site of the MV vector to generate MV-BLG-CAT which was amplified by standard bacterial culture and the plasmid subsequently purified on a CsCl gradient.
- This construct was compared to that of the original BLG-CAT gene in transient and stable transfections in cell culture using the mouse mammary cell line HC-11.
- the HC-11 cells were seeded in RPMI 1640 medium and incubated until they were 70% confluent. At this stage, the medium was changed and fresh medium was added.
- a mix comprising 20 ⁇ g of test DNA, 3 ⁇ g of a plasmid containing the neomycin phosphotransferase gene, 62 ⁇ l of 2M CaCl 2 , 0.5ml distilled water and 0.5 ml of 2X Hepes buffer was made up and 1.0 ml of this mixture was added to the cultured cells. The cells and DNA/CaCl 2 mix were then incubated overnight and after this the culture was split in half.
- transfected culture was incubated for a further 48 hours in medium containing the hormone prolactin to induce transient expression from the BLG promoter.
- the other half of the culture was incubated until 90% confluent and then the antibiotic G418 added to a final concentration of 200 ⁇ g/ml. G418 selection was continued or a further 2 weeks to select stable transformants .
- induction medium containing the hormone prolactin was added and the cells incubated for a further 2 days to induce BLG expression. Both transiently-transfected and stably-transfected cell populations were harvested by gentle centrifugation at the end of the culturing.
- CAT assays were carried out on protein extracts prepared by freeze-thawing the pellet of cells from both transiently- and stably-transfected cultures. The protein concentration in each sample was measured using the BioRad protein assay kit. CAT activity was assayed in a final volume of 100-200 ⁇ l using l-10 ⁇ g of protein extract in 0.25M Tris, pH8.8 with 14 C-chloramphenicol . The reaction was started using 5 ⁇ l of 50mM acetyl CoA incubated at 37°C for up to 3 hours and then the reaction was stopped using an equal volume of ethyl acetate.
- MV sequences to enhance expression from an SV40 enhancer promoter-CAT construct in fibroblast cells
- the above experiment shows that incorporation of MV sequences can be used to enhance expression from a BLG- CAT construct in stably transfected mammary gland cells in culture .
- the construct MV-SV40-CAT was prepared.
- the SV40-CAT gene comprises the SV40 enhancer promoter linked to the CAT gene and is analogous to the BLG-CAT gene described in Example 9, except that the BLG promoter is now replaced with SV40 regulatory sequences.
- the construction of MV-SV40-CAT is illustrated in Figure 11.
- the 1.4kb SV40-CAT sequences were released from the plasmid pB9SV by digestion with Hindlll and Xbal . The "sticky" ends from these fragments were filled in using Klenow polymerase and cloned into the Smal site of the MV vector to generate MV-SV40-CAT.
- SV40-CAT and MV-SV40-CAT constructs were compared in transient and stable transfections of baby hamster kidney (BHK) fibroblasts .
- BHK cells were seeded in Dulbecco's medium and incubated until 30-40% confluent and 3 hours prior to transfection the medium was changed.
- a mix comprising 20 ⁇ g of test DNA (SV40-CAT or MV-SV40-CAT) , 3 ⁇ g of a plasmid encoding the neomycin phosphotransferase gene, 62 ⁇ l of 2M CaCl 2 , 0.5ml of distilled water and 0.5ml of Hepes buffer was made up and 1.0ml of this mixture was added to the cultured cells.
- the cells and DNA/CaCl 2 mix were then incubated overnight and after this the culture was split in half. For transient transfections the cells were incubated for a further 48 hours and then assayed for CAT expression.
- FIG. 12 This figure shows the &CAT conversion, which is a measure of the expression level of the SV40-CAT construct, with and without MV sequences. Incorporation of the MV sequences had no effect on the expression levels of the SV40-CAT transgene after transient expression. However, there was an about 4.5-fold improvement in the level of expression when MV-SV40-CAT was compared to SV40-CAT in the stably transfected cell lines. These results show that the MV sequences can enhance the expression of CAT driven by a non-milk protein gene promoter (i.e. SV40) in non-mammary gland cell lines such as BHK fibroblasts.
- a non-milk protein gene promoter i.e. SV40
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU47109/97A AU4710997A (en) | 1996-10-14 | 1997-10-14 | Transgene expression |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9621383.0A GB9621383D0 (en) | 1996-10-14 | 1996-10-14 | Transgene expression |
GB9621383.0 | 1996-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998016634A1 true WO1998016634A1 (fr) | 1998-04-23 |
Family
ID=10801385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1997/002830 WO1998016634A1 (fr) | 1996-10-14 | 1997-10-14 | Expression transgene |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU4710997A (fr) |
GB (1) | GB9621383D0 (fr) |
WO (1) | WO1998016634A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002016625A2 (fr) | 2000-08-25 | 2002-02-28 | Basf Plant Science Gmbh | Polynucleotides vegetaux codant de nouvelles proteases prenyle |
US6576464B2 (en) | 2000-11-27 | 2003-06-10 | Geron Corporation | Methods for providing differentiated stem cells |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988000239A1 (fr) * | 1986-06-30 | 1988-01-14 | Pharmaceutical Proteins Ltd | Production de peptides |
WO1990005188A1 (fr) * | 1988-11-11 | 1990-05-17 | Pharmaceutical Proteins Limited | Structure genetique dont l'adn codant des proteines comprend des introns et est conçu pour faire produire des proteines a des animaux transgeniques |
WO1992011358A1 (fr) * | 1990-12-24 | 1992-07-09 | The Agricultural And Food Research Council | Expression amelioree dans des organismes transgeniques au moyen d'une seconde sequence transferee |
WO1996017946A1 (fr) * | 1994-12-06 | 1996-06-13 | Ppl Therapeutics (Scotland) Ltd. | Produit de construction de transgenes et son expression amelioree |
-
1996
- 1996-10-14 GB GBGB9621383.0A patent/GB9621383D0/en active Pending
-
1997
- 1997-10-14 AU AU47109/97A patent/AU4710997A/en not_active Abandoned
- 1997-10-14 WO PCT/GB1997/002830 patent/WO1998016634A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988000239A1 (fr) * | 1986-06-30 | 1988-01-14 | Pharmaceutical Proteins Ltd | Production de peptides |
WO1990005188A1 (fr) * | 1988-11-11 | 1990-05-17 | Pharmaceutical Proteins Limited | Structure genetique dont l'adn codant des proteines comprend des introns et est conçu pour faire produire des proteines a des animaux transgeniques |
WO1992011358A1 (fr) * | 1990-12-24 | 1992-07-09 | The Agricultural And Food Research Council | Expression amelioree dans des organismes transgeniques au moyen d'une seconde sequence transferee |
WO1996017946A1 (fr) * | 1994-12-06 | 1996-06-13 | Ppl Therapeutics (Scotland) Ltd. | Produit de construction de transgenes et son expression amelioree |
Non-Patent Citations (4)
Title |
---|
A.S. CARVER ET AL.: "Transgenic livestock as bioreactors: Stable expression of human alspha-1-antitrypsin by a flock of sheep", NATURE BIOTECHNOLOGY, vol. 11, no. 11, November 1993 (1993-11-01), NATURE PUBL. CO.,NEW YORK, US, pages 1263 - 1269, XP002053857 * |
CLARK A J ET AL: "CHROMOSOMAL POSITION EFFECTS AND THE MODULATION OF TRANSGENE EXPRESSION", REPRODUCTION, FERTILITY AND DEVELOPMENT, vol. 6, no. 5, 1 January 1994 (1994-01-01), pages 589 - 598, XP000564397 * |
DOBIE K W ET AL: "VARIEGATED TRANSGENE EXPRESSION IN MOUSE MAMMARY-GLAND IS DETERMINED BY THE TRANSGENE INTEGRATION LOCUS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (25 JUN 1996) VOL. 93, NO. 13, PP. 6659-6664. ISSN: 0027-8424., XP002053858 * |
R. AL-SHAWI ET AL.: "Expression of a foreign gene in a line of transgenic mice is modulated by a chromosomal position effect", MOL. CELL. BIOL., vol. 10, no. 3, March 1990 (1990-03-01), ASM WASHINGTON, DC,US, pages 1192 - 1198, XP002053859 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002016625A2 (fr) | 2000-08-25 | 2002-02-28 | Basf Plant Science Gmbh | Polynucleotides vegetaux codant de nouvelles proteases prenyle |
US6576464B2 (en) | 2000-11-27 | 2003-06-10 | Geron Corporation | Methods for providing differentiated stem cells |
US8426198B2 (en) | 2000-11-27 | 2013-04-23 | Geron Corporation | In vitro differentiated cell and human embryonic stem cell population |
US9023645B2 (en) | 2000-11-27 | 2015-05-05 | Asterias Biotherapeutics, Inc. | Isolated in vitro cell population comprising primate pluripotent stem cells containing a nucleic acid construct and differentiated progeny of the pluripotent stem cells |
Also Published As
Publication number | Publication date |
---|---|
GB9621383D0 (en) | 1996-12-04 |
AU4710997A (en) | 1998-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chikashige et al. | Composite motifs and repeat symmetry in S. pombe centromeres: direct analysis by integration of Notl restriction sites | |
Sched et al. | A method for the generation of YAC transgenic mice by pronuclear microinjection | |
Orban et al. | Tissue-and site-specific DNA recombination in transgenic mice. | |
Loukeris et al. | Introduction of the transposable element Minos into the germ line of Drosophila melanogaster. | |
Kondo et al. | High-level expression of a sweet protein, monellin, in the food yeast Candida utilis | |
US6891031B2 (en) | Coordinate cytokine regulatory sequences | |
US6120764A (en) | Adenoviruses for control of gene expression | |
JPS63309192A (ja) | 効率的な分泌のための乳腺に出される蛋白におけるdna配列 | |
CA2203569A1 (fr) | Sequence nucleotidique codant l'enzyme i-scei et ses utilisations | |
DE705334T1 (de) | Strenge kontrolle der genexpression in eukaryotischen zellen durch auf tetrazyklin ansprechende promotoren | |
JP2000515011A (ja) | 形質転換関連組換えクローニング | |
US6090554A (en) | Efficient construction of gene targeting vectors | |
CA2300972A1 (fr) | Utilisation de l'element mariner pour creer des animaux transgeniques | |
AU661290B2 (en) | Increased expression by a second transferred sequence in transgenic organisms | |
WO2001040477A1 (fr) | Transposase et procede de modification de genes | |
Szelei et al. | Liposome-mediated gene transfer in fish embryos | |
US5614398A (en) | Gene transfer system for insects | |
US5714345A (en) | Increased expression of a gene by a second transferred mammary gland specific sequence transgenic | |
EA020311B1 (ru) | Вектор на основе искусственной хромосомы | |
WO1998016634A1 (fr) | Expression transgene | |
Sands et al. | Cytoplasmic β‐actin promoter produces germ cell and preimplantation embryonic transgene expression | |
Fujiwara et al. | Analysis of control elements for position‐independent expression of human α‐lactalbumin YAC | |
Montoliu et al. | Generation of transgenic mice with yeast artificial chromosomes | |
US7053262B2 (en) | Mammary gland tissue-specific expression system using β-casein promoter site of Korean native goat | |
US5827687A (en) | Promoter and method of gene expression using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998518108 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase |